Woodline Partners’s Apellis Pharmaceuticals APLS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-976,175
| Closed | -$39.3M | – | 1027 |
|
|
2026
Q1 | $39.3M | Buy |
976,175
+433,194
| +80% | +$9.33M | 0.15% | 180 |
|
|
2025
Q4 | $13.6M | Hold |
542,981
| – | – | 0.05% | 385 |
|
|
2025
Q3 | $12.3M | Buy |
542,981
+12,058
| +2% | +$281K | 0.06% | 393 |
|
|
2025
Q2 | $9.19M | Buy |
530,923
+312,073
| +143% | +$5.78M | 0.05% | 447 |
|
|
2025
Q1 | $4.79M | Buy |
218,850
+29,373
| +16% | +$811K | 0.03% | 520 |
|
|
2024
Q4 | $6.05M | Buy |
189,477
+913
| +0.5% | +$27.5K | 0.04% | 446 |
|
|
2024
Q3 | $5.44M | Buy |
188,564
+1,564
| +0.8% | +$57.9K | 0.05% | 379 |
|
|
2024
Q2 | $7.17M | Buy |
187,000
+2
| +0% | +$91 | 0.07% | 292 |
|
|
2024
Q1 | $11M | Buy |
186,998
+774
| +0.4% | +$49.3K | 0.1% | 249 |
|
|
2023
Q4 | $11.1M | Buy |
+186,224
| New | +$9.45M | 0.12% | 217 |
|
|
2023
Q1 | – | Sell |
-70,651
| Closed | -$3.65M | – | 633 |
|
|
2022
Q4 | $3.65M | Buy |
+70,651
| New | +$3.75M | 0.05% | 368 |
|
|
2022
Q1 | – | Sell |
-41,199
| Closed | -$1.95M | – | 721 |
|
|
2021
Q4 | $1.95M | Sell |
41,199
-66,877
| -62% | -$2.63M | 0.03% | 425 |
|
|
2021
Q3 | $3.56M | Buy |
+108,076
| New | +$6.07M | 0.06% | 306 |
|
|
2021
Q2 | – | Sell |
-171,419
| Closed | -$7.36M | – | 592 |
|
|
2021
Q1 | $7.36M | Buy |
+171,419
| New | +$8.11M | 0.16% | 159 |
|
|
2020
Q2 | – | Sell |
-224,948
| Closed | -$6.03M | – | 153 |
|
|
2020
Q1 | $6.03M | Buy |
224,948
+92,001
| +69% | +$3.27M | 0.43% | 73 |
|
|
2019
Q4 | $4.07M | Buy |
+132,947
| New | +$3.68M | 0.17% | 95 |
|
Other funds holding APLS
Woodline Partners's APLS Position: Q2 2026 in Review
Woodline Partners sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 976,175 shares — an estimated $39.3M sold.
Woodline Partners first reported a position in APLS in Q4 2019 and held it in 16 quarters. The position peaked at $39.3M in Q1 2026. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.
- Woodline Partners reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- Woodline Partners sold 976,175 Apellis Pharmaceuticals shares in Q2 2026, an estimated $39.3M.
- Woodline Partners first reported a position in Apellis Pharmaceuticals in Q4 2019 and held it in 16 quarters.
- Woodline Partners's Apellis Pharmaceuticals position peaked at $39.3M in Q1 2026.
- 1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.
Based on Woodline Partners's 13F filing for Q2 2026, filed 14 Aug 2026.